| Salas |
Postnatal Growth as Stand-Alone Predictor of Cognition at 2 Years of Age in Extremely Preterm Infants |
Poster |
1419828 |
| Sankar |
PDA Treatments and Hydrocortisone exposure in extremely preterm infants: A secondary analysis of the Hydrocortisone Trial. |
Poster |
1420266 |
| Natarajan |
Can Total Sarnat Score Predict Outcome in Moderate or Severe Hypoxic-Ischemic Encephalopathy (HIE)? |
Poster |
1424057 |
| Brumbaugh |
Redirection of Care in Relation to Social Determinants of Health for Infants Born Extremely Preterm |
Oral Abstract |
1393760 |
| Faix |
Randomized trial of targeted temperature management with whole body hypothermia for moderate and severe neonatal encephalopathy (NE) in premature infants 33-0/7 to 35-6/7 wk gestational age (GA) |
Oral Abstract |
1397142 |
| Minor |
Survival, major morbidities, and neurodevelopmental impairment in extremely preterm, small for gestational age infants |
Oral Abstract |
1415332 |
| Shankaran |
Magnetic Resonance Imaging (MRI) in Term Infants with Hypoxic-Ischemic Encephalopathy (HIE) in the Optimizing Cooling Strategies Trial |
Oral Abstract |
1411784 |
| Ohls |
Darbepoetin (Darbe) Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants |
Oral Abstract |
1424785 |
| Arnold |
Unbound Bilirubin and Risk of Severe Neurodevelopmental Impairment in Extremely LowBirthweight (ELBW) newborns |
Poster |
1413560 |
| Messick |
Impact of Maternal COVID-19 on Outcomes of Extremely Preterm Infants in the Neonatal Intensive Care Unit (NICU) |
Oral Abstract |
1421232 |
| Kaluarachchi |
Secular Trends in Patent Ductus Arteriosus Management in Preterm Infants within the Neonatal Research Network |
Poster |
1425037 |
| Chawla |
Association of Antenatal Steroid Exposure at <= 22 Weeks of Gestation with Survival without Severe Neurodevelopmental Impairment |
Poster |
1423360 |
